Hutchison Pharmaceutical Co., Ltd. announced today that its subsidiary Hutchison Whampoa Pharmaceutical Co., Ltd. has reached an exclusive development and licensing agreement with a subsidiary of GSK plc, granting the GlaxoSmithKline subsidiary the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau and Taiwan. The agreement includes a $110 million down payment and potential development, registration and commercialization milestone payments, totaling up to $1,295 million, plus royalties based on net sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.